NCT06203223 is a NA clinical trial of Ova-max in Female, sponsored by Aristotle University Of Thessaloniki.

Who is sponsoring NCT06203223?

NCT06203223 is sponsored by Aristotle University Of Thessaloniki.

What drugs are being tested in NCT06203223?

Interventions in NCT06203223: Ova-max, placebo.

What condition does NCT06203223 study?

NCT06203223 studies Female, Infertility.

Is NCT06203223 still recruiting?

NCT06203223 is currently terminated. Last updated 20 May 2025.

Last reviewed 2025-05-20 · How we verify

NCT06203223

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Effect of Ovamax on Oocyte Quality

Terminated NA Last updated 20 May 2025

What this trial tests

NA trial testing Ova-max in Female in 97 participants. Terminated before completion.

Timeline

1 July 2021

Primary endpoint
30 November 2024

15 January 2025

Quick facts

Lead sponsor	Aristotle University Of Thessaloniki
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	97
Start date	1 July 2021
Primary completion	30 November 2024
Estimated completion	15 January 2025
Sites	1 location across Greece

Drugs / interventions tested

Ova-max
placebo

Conditions studied

Female — all drugs for Female →
Infertility — all drugs for Infertility →

Sponsor

Aristotle University Of Thessaloniki

Who can join

Adults 18 to 46, female only, with Female or Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Oocyte quality is a basic parameter that affects embryo quality and therefore it influences the outcome of assisted reproduction. It has been suggested that oocyte quality is improved by the intake of vitamins and antioxidants. Ova-Max is a dietary supplement that consists of vitamins, minerals and antioxidants which improve women's oocytes by preventing oxidative stress. Specifically, Ovamax includes Chasteberry, Melatonin, Myo-Inositol, Folic Acid, Co-Enzyme Q10, Vitamin E, L-Arginine, Grape seed extract and Alpha-lipoic Acid. The purpose of this study is to evaluate the influence of Ova-max intake on oocyte quality in women undergoing In Vitro Fertilization. According to the research hypothesis the administration of Ova-Max for three months increases oocyte quality in women undergoing intracellular sperm injection after ovarian stimulation and oocyte retrieval.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Female

Currently open trials in the same condition.

NCT07415798 — A Quantitative, Cross-Sectional and Observational Study to Characterize Age-Related Structural Changes in Facial Skin of · recruiting
NCT07336147 — Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine · Phase 2 · recruiting
NCT06985745 — Emulsion 8-Week Anti-acne Efficacy Clinical Study · NA · active not recruiting
NCT07153861 — Oral Mucosal Graft Versus Labial Graft in Female Urethroplasty · NA · recruiting
NCT07026383 — Physiological and Psychological Profiles · recruiting

Other Aristotle University Of Thessaloniki trials

Trials by the same sponsor.

NCT07382479 — NeoAdjuvant ChemoTherapy With KELIM Guided Interval vs. Delayed Interval Debulking Surgery · NA · not yet recruiting
NCT07379905 — MODUCARE Versus Wait-and-See Approach for Histologically Proven Low-grade Cervical Intraepithelial Neoplasia (CIN1) · NA · not yet recruiting
NCT07335016 — The Role of Follicular Flushing at Oocyte Retrieval · NA · not yet recruiting
NCT07297121 — Validation of the Montreal Cognitive Assessment (MoCA) Version 8.x and MoCA-MIS in Greece. · not yet recruiting
NCT07210164 — Pre-habilitation Within ERAS Protocol for Gynecologic Oncology Surgery: The Pre_ERAS Study · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06203223 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aristotle University Of Thessaloniki
Last refreshed: 20 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06203223.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing